Harbourvest Partners’s Seres Therapeutics MCRB Stock Holding History

Harbourvest Partners’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2,468	Closed	-$46.7K	–	28
2024 Q3	$46.7K	Hold	2,468	–	–	0.02%	29
2024 Q2	$35.7K	Hold	2,468	–	–	0.02%	34
2024 Q1	$38.2K	Hold	2,468	–	–	0.02%	44
2023 Q4	$69.1K	Hold	2,468	–	–	0.02%	48
2023 Q3	$117K	Hold	2,468	–	–	0.04%	51
2023 Q2	$236K	Hold	2,468	–	–	0.07%	47
2023 Q1	$280K	Hold	2,468	–	–	0.09%	48
2022 Q4	$276K	Hold	2,468	–	–	0.09%	48
2022 Q3	$317K	Hold	2,468	–	–	0.1%	53
2022 Q2	$169K	Hold	2,468	–	–	0.06%	55
2022 Q1	$351K	Hold	2,468	–	–	0.07%	55
2021 Q4	$411K	Hold	2,468	–	–	0.05%	51
2021 Q3	$344K	Hold	2,468	–	–	0.03%	47
2021 Q2	$1.18M	Hold	2,468	–	–	0.11%	32
2021 Q1	$1.02M	Sell	2,468 -1,727	-41%	-$795K	0.14%	24
2020 Q4	$2.06M	Buy	+4,195	New	+$2.46M	0.8%	12

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Harbourvest Partners's MCRB Position: Q4 2024 in Review

Harbourvest Partners sold out of Seres Therapeutics (MCRB) in Q4 2024, closing a stake of 2,468 shares — an estimated $46.7K sold.

Harbourvest Partners first reported a position in MCRB in Q4 2020 and held it in 16 quarters. The position peaked at $2.06M in Q4 2020. 69 funds tracked by Wall St. Rank hold MCRB as of Q4 2024.

Harbourvest Partners reported no remaining Seres Therapeutics position as of Q4 2024 after selling out during the quarter.
Harbourvest Partners sold 2,468 Seres Therapeutics shares in Q4 2024, an estimated $46.7K.
Harbourvest Partners first reported a position in Seres Therapeutics in Q4 2020 and held it in 16 quarters.
Harbourvest Partners's Seres Therapeutics position peaked at $2.06M in Q4 2020.
69 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2024.

Based on Harbourvest Partners's 13F filing for Q4 2024, filed 14 Feb 2025.